



Sensorion to have Significant Presence at ARO MidWinter Meeting 2017

Inner Ear Pipeline Products Subject of Podium and Poster Presentations

Montpellier, December 14, 2016 - Sensorion (FR0012596468 – ALSEN), a biotech company specializing in the treatment of inner ear diseases, today announces that it will participate in a podium presentation and present three posters at the 40th Association for Research in Otolaryngology (ARO) MidWinter Meeting in Baltimore, MD, which takes place from February 11 to 15, 2017.

The ARO MidWinter Meeting is the benchmark international congress for researchers and clinicians working in the field of Ear Nose and Throat (ENT) pathologies. The four Sensorion studies selected by the Meeting's reading committee to be presented are:

Podium presentation:

- *Translational Predictivity of Preclinical Model Studies of the Anti-Vertigo Drug SENS-111 for Clinical PK/PD Relationships*

Poster presentations:

- *SENS-111, a new H₄R antagonist, concentration dependently reduces vertigo sensation in healthy volunteers (HV)*
- *Treatment Window for Oral Administration of the Clinical Drug Candidate SENS-401 after Acoustic Trauma in Rat*
- *Comparative Characterization of Vertigo Associated Symptoms in a Preclinical Model Using Videonystagmography and Wireless Inertial Measurement of Head Kinematics*

Pierre Attali, Sensorion's Chief Medical Officer, comments: "Sensorion is pleased to have the opportunity to participate in a scientific meeting as important as the ARO MidWinter Meeting. We are delighted that our R&D programs in vertigo and hearing loss continue to garner significant interest within the scientific community."

...

About SENS-111

SENS-111 is the first histamine type 4 receptor antagonist tested in inner-ear pathologies. This drug candidate displays a neuromodulation effect of the sensorineural inner ear cell function and is being developed for the symptomatic treatment of vertigo crises and tinnitus. SENS-111 is a small molecule that can be taken orally or via a standard injection, and has been successfully assessed in humans in phase 1b. Sensorion has set up a phase 2 clinical trial to assess this drug candidate in 207 patients with acute unilateral vestibulopathy, with enrolment due to begin during the first quarter of 2017.

About SENS-401

SENS-401, R-azasetron besylate, is a drug candidate that aims to protect and preserve inner ear tissue when lesions are present that can cause progressive or sequelar hearing impediments. It is one of the two enantiomer forms of SENS-218, azasetron, a racemic molecule belonging to the family of setrons marketed in Asia under the name Serotone. Enantiomers are molecules that have an identical chemical structure but a different configuration in space, i.e. they are mirror images of each other, like a person's left and right hands. The pharmacological and pharmacokinetic tests completed to date have shown a superior drug candidate profile for SENS-401 compared with the other enantiomer or the racemic form. SENS-401 is a small molecule that can be taken orally or via an injection and has received Orphan Drug Designation in Europe for the treatment of sudden sensorineural hearing loss.

About Sensorion

Sensorion specializes in the treatment of pathologies of the inner ear such as acute vertigo, tinnitus and hearing loss. The company was founded by Inserm (the French Institute of Health and Medical Research) and is utilizing its pharmaceutical R&D experience and comprehensive technology platform to develop first-in-class easy-to-administer, notably orally active, drug candidate programs for treating hearing loss and the symptoms of vertigo and tinnitus, for preventing and treating complications associated with progressive lesions in the inner ear, and for preventing the toxicity of chemotherapy in the inner ear. Based in Montpellier, southern France, Sensorion received financial support from Bpifrance, through the InnoBio fund, and Inserm Transfert Initiative.

Sensorion has been listed on the Euronext Alternext Paris exchange since April 2015. www.sensorion-pharma.com

Contacts

Sensorion

Laurent Nguyen
CEO

contact@sensorion-pharma.com

Tel: +33 (0)4 67 20 77 30

Name: **SENSORION**

ISIN code: **FR0012596468**

Ticker: **ALSEN**



International Investor Relations

NewCap

Dusan Oresansky / Emmanuel Huynh

sensorion@newcap.eu

Tel: +33 (0)1 44 71 94 92

Investor Relations – Rest of the World

LifeSci Advisors LLC

Chris Maggos – Managing Director, Europe

chris@lifesciadvisors.com

Tel.: +41 79 367 6254

Disclaimer

This press release contains certain forward-looking statements concerning Sensorion and its business. Such forward-looking statements are based on assumptions that Sensorion considers to be reasonable. However, there can be no assurance that such forward-looking statements will be verified, which statements are subject to numerous risks, including the risks set forth in the *Document de référence* registration document filed with the *Autorité des marchés financiers* (AMF- French Financial Market Authority) on July 28, 2016 under n°R.16-069 and to the development of economic conditions, financial markets and the markets in which Sensorion operates. The forward-looking statements contained in this press release are also subject to risks not yet known to Sensorion or not currently considered material by Sensorion. The occurrence of all or part of such risks could cause actual results, financial conditions, performance or achievements of Sensorion to be materially different from such forward-looking statements.

This press release and the information that it contains do not constitute an offer to sell or subscribe for, or a solicitation of an offer to purchase or subscribe for, Sensorion shares in any country. The communication of this press release in certain countries may constitute a violation of local laws and regulations. Any recipient of this press release must inform oneself of any such local restrictions and comply therewith.